For atherosclerotic cardiovascular diseases (ACD), gene therapy may be a potential therapeutic strategy; however, lack of effective and safe methods for gene delivery to atherosclerotic plaques have limited its potential therapeutic applications. To overcome this limitation, we developed a novel antibody-based gene delivery system (anti-HB-EGF/NA vector) by chemically crosslinking antibodies against human heparin-binding epidermal growth factor-like growth factor (HB-EGF). It has been shown to be excessively expressed in human atherosclerotic plaques and NeutrAvidin (NA) for conjugating biotinylated siRNA. Immunofluorescence staining and quantitative flow cytometry analysis using human HB-EGF-expressing cells showed both antibody-mediated selective cellular targeting and efficient intracellular delivery of conjugated biotin-fluorescence. Moreover, we demonstrated antibody-mediated significant and selective gene knockdown via conjugation with anti-HB-EGF/ NA vector and biotinylated siRNA (anti-HB-EGF/NA/b-siRNA) in vitro. Furthermore, using high fat-fed human HB-EGF knock-in and apolipoprotein E-knockout (Hbegf hz/hz; Apoe-/-) mice, we demonstrated that the anti-HB-EGF/NA vector, conjugating biotin-fluorescence, increasingly accumulated within the atherosclerotic plaques of the ascending aorta in which human HB-EGF expression levels were highly elevated. Moreover, in response to a single intravenous injection of anti-HB-EGF/NA/b-siRNA in a dose-dependent manner, qPCR analysis of laser-dissected atherosclerotic plaques of the ascending aorta showed significant knockdown of the reporter gene expression. These results suggest that the anti-HB-EGF antibody-mediated siRNA delivery could be a promising delivery system for gene therapy of ACD.
I
n industrialized countries, atherosclerotic cardiovascular diseases (ACD), such as acute myocardial infarction and strokes, are the leading causes of death and morbidity. 1, 2) Although lowering the low-density lipoprotein can reduce the burden of atherosclerotic lesions, current treatments are insufficient in preventing the progression of atherosclerosis. 3) Recently, gene transfer and gene silencing using viral vectors are being explored as potential atherosclerosis and cancer treatment strategies. 4) However, viral vectors are generally associated with safety concerns such as carcinogenesis and immunogenicity; 5) therefore, for treating cancer, siRNA delivery using antibodies has been applied. 6) However, to our knowledge, there have been no reports related to non-viral gene delivery or evaluation of knockdown efficiency of these systems for atherosclerotic lesions.
Note that atherosclerotic lesions are characterized by persistent inflammatory responses, which involve macrophages and smooth muscle cells (SMCs) [7] [8] [9] as well as membrane-anchored forms of heparin-binding epidermal growth factor-like growth factor (HB-EGF), a diphtheria toxin receptor. After binding, this receptor is internalized 10) and excessively expressed in macrophages and SMCs within atherosclerotic plaques. 11, 12) We previously demonstrated that anti-HB-EGF antibody (Ab) (Fab' fragment)-modified liposomes could deliver drugs or siRNA to cancer cells expressing HB-EGF.
Tsuchida, ET AL HB-EGF/NA/b-siRNA) and examined whether it could suppress the expression of target molecules within the atherosclerotic plaques in mice.
Methods

Materials:
A bicinchoninic acid (BCA) kit and toluidine blue O was purchased from Sigma-Aldrich (St. Louis, Missouri, USA). Using a previously described method, monoclonal anti-human HB-EGF Ab clone 0F0464 (anti-HB-EGF) was obtained. 15) Then, biotinylated siRNAs (bsiRNA) were custom synthesized at GeneDesign, Inc. (Osaka, Japan). Note that the sequence for luciferase GL3 siRNA has been previously reported.
16) The sequence for humanized Renilla Green Fluorescent Protein (hrGFP) siRNA was 5'-AGGGCGUGGUGAAGGACUUdTdT-3' (sense) and 5'-AAGUCCUUCACCACGCCCUdTdT-3' (antisense). To prevent siRNA degradation, all siRNAs were modified using 2'-fluorouridine (2'-FU) and 2'-fluorocytidine (2'-FC).
17)
Synthesis of anti-HB-EGF Ab-conjugated NA (anti-HB-EGF/NA): As previously reported, anti-HB-EGF Ab was conjugated to NA using N-[(4-maleimidomethyl) cyclohexylcarbonyloxy]sulfosuccinimide, sodium salt (sulfo-SMCC) and 2-iminothiolane with minor modifications. 18) Using sulfo-SMCC, maleimide groups were introduced into the anti-HB-EGF Ab, whereas free sulfhydryl groups were introduced into NA using 2-iminothiolane according to the manufacturer's instructions (Thermo Fisher Scientific, Waltham, Massachusetts, USA). To generate anti-HB-EGF/NA, a sulfo-SMCC-derivatized anti-HB-EGF Ab and thiolated NA were mixed in a molar ratio of 1:10. Anti-HB-EGF/NA was isolated from unreacted NA using a Protein G column (GE Healthcare, Buckinghamshire, UK). To generate anti-HB-EGF/NA/b-siRNA, anti-HB-EGF/NA and b-siRNA were mixed at a molar ratio of 1: 2.5. Then, to generate anti-HB-EGF/NA-labeled fluorescent ATTO488 or ATTO700 (AttoTec, Siegen, Germany), anti-HB-EGF/NA was immobilized onto Protein G Sepharose beads. After applying biotinylated fluorescence and removing unreacted molecules, the anti-HB-EGF/NAlabeled fluorescent molecules were eluted. Characteristics of anti-HB-EGF/NA: We measured the size of anti-HB-EGF/NA using the Zetasizer ZS System (Malvern, Worcestershire, UK) according to the manufacturer's instructions. Using a Biacore T200 System (GE Healthcare), affinity analyses were performed. Using the Mouse Ab Capture Kit, anti-HB-EGF Ab or an anti-HB-EGF/NA was bound to the CM5 sensor chip according to the manufacturer's instructions (GE Healthcare). To measure the binding affinity constant (KD), recombinant HB-EGF (Peprotech, Rocky Hill, New Jersey, USA) was used at different concentrations (0-100 nmol/L). The gel retardation assay was performed as previously reported with minor modifications. 19) Cell culture: All cell lines were maintained as previously described. 20) Confocal microscopy and flow cytometry (FACS) analysis: Vero cells with and without stable expression of human HB-EGF (Vero-H) were separately cultured. 21) These cells were treated with anti-HB-EGF/NA-labeled ATTO488 at 37°C for 1 hour. After washing with PBS, the cells were incubated for 0 or 24 hours at 37°C. For confocal microscopy analysis, the cells were treated with anti-mouse IgG-labeled Alexa594 (Thermo Fisher Scientific) and Hoechst 33342 (Dojindo Molecular Technologies, Kumamoto, Japan) for 1 hour on ice. Fluorescence was observed via confocal laser-scanning microscopy (LSM 710; Carl Zeiss, Jena, Germany). For FACS analysis, cell suspensions were treated with anti-mouse IgGlabeled PE (Phycoerythrin) (BioLegend, San Diego, California, USA) and 7-amino-actinomycin D (7-AAD, Thermo Fisher Scientific) for 1 hour on ice. Cell suspensions were analyzed using a FACS aria II flow cytometer (BD Biosciences, Franklin Lakes, New Jersey, USA). Individual cells were gated using forward and side scatter profiles, whereas living cells were gated using negative staining for 7-AAD, which also stains dead cells. Plasmid construction and generation of stable cell lines: Luciferase genes derived from pGL3 basic vector (Promega, Fitchburg, Wisconsin, USA) were subcloned into pcDNA3.1/Zeo (+) (Thermo Fisher Scientific) to generate pcDNA3.1/Zeo (+)/luciferase. For stably producing Vero cells that expressed luciferase (Vero-L) as well as Vero-H cells that stably expressed luciferase (Vero-HL), both Vero and Vero-H cells were transfected with pcDNA 3.1/Zeo (+)/luciferase using Lipofectamine 2000 (Thermo Fisher Scientific). Moreover, the transfectants were selected using zeocin-containing medium based on the manufacturer's instructions. Both Vero-L and Vero-HL cells were selected based on their luciferase activity with a luciferase assay reagent (Promega). Then, the luciferase activity was normalized for protein concentration using a BCA Protein Assay based on the manufacturer's instructions. In vitro knockdown experiments: Vero-L and Vero-HL cells were grown in DMEM supplemented with 10% FBS. The cells were then transfected with b-siRNA using anti-HB-EGF/NA or Lipofectamine RNAiMAX (Thermo Fisher Scientific) for 4 hours. Then, the cells were cultured for 48 hours, and luciferase activity was measured as described above. Mice and diets: Humanized HB-EGF knock-in mice (Hbegf hz/hz) in which the murine HB-EGF gene was replaced with the humanized HB-EGF (hzHB-EGF)-internal ribosome entry sites, hrGFP, 22) were crossed with the apolipoprotein E-knockout mice (Apoe-/-) (The Jackson Laboratory, Bar Harbor, Maine, USA) for generating Hbegf hz/ hz; Apoe-/-mice. The mice (7 weeks old) were fed with a high-fat diet (D12492; Research Diets, New Brunswick, New Jersey, USA) for 30 weeks. For in vivo knockdown of hrGFP expression, the mice were intravenously injected with 200 μL of solutions containing either 100 or 500 μg of anti-HB-EGF/NA/b-siRNA, only b-siRNA (the same amount of 500 μg of anti-HB-EGF/NA/b-siRNA) or saline and then sacrificed after 2 days. For accumulation analysis, the mice were intravenously injected with 200 μL of anti-HB-EGF/NA-labeled ATTO700 or saline and sacrificed after 1 hour. Using an IVIS Lumina II imaging system, fluorescence images of atherosclerotic aortas (from the ascending aorta to the abdominal aorta) were acquired (Perkin Elmer; Waltham, Massachusetts, USA).
NOVEL siRNA DELIVERY TO ATHEROSCLEROTIC LESIONS All the procedures were performed in accordance with the Osaka University Research Committee. All the animal experiments conformed to the Guide for the Care and Use of Laboratory Animals published by the US National Institutes of Health (the 8th Edition, NRC 2011). Staining of atherosclerotic plaques: For immunofluorescence staining, the sections were blocked in 10% block ace (DS Pharma, Osaka, Japan) and anti-mouse CD16/32 Ab (1/50, eBioscience, San Diego, USA) for 1 hour and incubated overnight at 4°C with the mouse monoclonal anti-human HB-EGF Ab-labeled ATTO550 (in-house) or mouse IgG isotype control Ab-labeled ATTO550 (inhouse) along with anti-α-action Ab-labeled FITC (1/50, Abcam, Massachusetts, USA). After washing with TBS-T, the sections were incubated with Hoechst 33342 and observed with a confocal microscope (lsm710).
Hematoxylin and eosin (HE) with Oil-red O staining was performed according to manufacturer's instructions, followed by microscopic examination (BZ-9000, KEY-ENCE, Tokyo, Japan). Laser microdissection and quantitative polymerase chain reaction (qPCR): For mRNA isolation from atherosclerotic lesions, serial frozen sections (30 μm, 30 slides/mouse) from the ascending aorta were obtained. These sections were stained with toluidine blue according to the manufacturer's instructions. After staining, the atherosclerotic lesion samples were isolated via laser microdissection (LMD7000, Leica Microsystems, Wetzlar, Germany). Because small amounts of RNA were obtained from each slide, we pooled samples from > 30 slides as one individual sample. The mRNA isolation was performed using the RNeasy Micro Kit (Qiagen, Valencia, California, USA). For mRNA isolation from heart, aorta (abdominal), lung, liver, kidney, and spleen, total RNA was isolated using RNA-Bee (Tel-Test, Friendswood, Texas, USA) according to the manufacturer's instructions.
After mRNA isolation, reverse transcription was performed using the High-Capacity cDNA Reverse Transcription Kit (Thermo Fisher Scientific), whereas qPCR was performed using a ViiA 7-Real Time PCR System (Thermo Fisher Scientific). The hrGFP forward (GCAAGGGCAACATCCTGTTC) and reverse (TCAG-GATGTCGAAGGCGAAG) primers were purchased from Greiner Bio One (Frickenhausen, Germany). Moreover, the primers for GAPDH (Mm99999915_g1) were obtained from Thermo Fisher Scientific. Statistics: Statistical analysis was performed with oneway ANOVA and Tukey's post hoc test using GraphPad 6 (GraphPad, La Jolla, CA, USA). The data are expressed as means ± SEM or means ± SD. A P value less than 0.05 was considered to be statistically significant.
Results
HB-EGF expression in atherosclerotic lesions:
To confirm phenotypes of Hbegf hz/hz; Apoe-/-mice fed a highfat diet for 30 weeks, their ascending aorta was stained with HE and Oil-red O. As shown in Figure 1A , Hbegf hz/hz; Apoe-/-mice, rather than Hbegf hz/hz mice fed normal chow for 30 weeks, developed atherosclerotic lesions. To investigate protein expression levels of HB-EGF in atherosclerotic lesions, we performed immunostaining for the ascending aorta in Hbegf hz/hz; Apoe-/-mice. As shown in Figure 1B , HB-EGF protein was detected in the atherosclerotic lesions. To compare expression levels of HB-EGF within each organ, we examined mRNA levels of hrGFP, which was transcribed as a bicistronic mRNA with human HB-EGF, using qRT-PCR. As shown in Figure 1C , compared with heart, aorta (abdominal), lung, liver, kidney, and spleen tissue, hrGFP mRNA levels were highest in atherosclerotic lesions. In Hbegf hz/hz mice, the expression of HB-RGF in the aorta did not significantly differ from that in the heart or lungs (data not shown). Characteristics of anti-HB-EGF/NA: Size and binding affinity constants (KD) of anti-HB-EGF Ab and anti-HB-EGF/NA are shown in the Table. The size of anti-HB-EGF/NA increased, whereas the KD for this molecule decreased compared with anti-HB-EGF Ab. To investigate the mix ratio of b-siRNA and anti-HB-EGF/NA and to obtain maximum binding, we performed a gel retardation assay. At the molar ratio of 2.5:1, almost all b-siRNAs were complexed with anti-HB-EGF/NA (data not shown). Figure 2A , the anti-HB-EGF/NA-labeled ATTO488 could bind to and undergo internalization within Vero-H, but not Vero, cells within 24 hours. Consistently, FACS analysis using anti-mouse IgG Ab-labeled PE, which recognizes anti-HB-EGF/NAlabeled ATTO488, showed that anti-HB-EGF/NA-labeled ATTO488 could bind to and undergo internalization into Vero-H, but not Vero, cells. As shown in Figure 2B , the PE fluorescence's intensity increased in Vero-H, but not Vero, cells after 1 hour of incubation. This suggests that anti-HB-EGF/NA-labeled ATTO488 could bind to the HB-EGF on the membrane of Vero-H cells. However, the PE fluorescence's intensity in Vero-H cells decreased~80% after 24 hours, suggesting that~80% of the anti-HB-EGF/ NA-labeled ATTO488 bound to HB-EGF on the cell surface was internalized within Vero-H cells.
Selective binding and internalization of anti-HB-EGF/ NA-labeled fluorescence in Vero-H cells: To determine whether anti-HB-EGF/NA could selectively bind to and undergo internalization in cells that expressed HB-EGF, we incubated Vero and Vero-H cells with anti-HB-EGF/ NA-labeled ATTO488. As shown in
Selective delivery of anti-HB-EGF/NA/b-siRNA into Vero-H cells:
To investigate whether anti-HB-EGF/NA/bsiRNA could suppress target genes in vitro, at 48 hours after treatment, we examined the luciferase activity for both Vero-L and Vero-HL cells, both of which stably expressed luciferase. As shown in Figure 3 Frozen tissue sections were stained red using an anti-HB-EGF Ab (upper panels) or mouse IgG isotype control antibody-labeled ATTO550 (lower panels). The sections were co-stained for α-actin (green) and Hoechst (blue). Scale bars indicate 50 μm. C: Tissue hrGFP expression levels were evaluated by qRT-PCR. GAPDH served as an internal control. Data are presented as means ± SEM (n = 3). The sizes were measured using Zetasizer Nano ZS. The binding affinity constants were measured using a Biacore T 200 system. The data are presented as means ± SD (n = 3).
were fed with normal chow for 30 weeks. As shown in Figure 4A , anti-HB-EGF/NA-labeled ATTO700 accumulated from the ascending aorta to the arch region in Hbegf hz/hz; Apoe-/-mice but not in the Hbegf hz/hz mice. To investigate whether anti-HB-EGF/NA/b-siRNA suppressed the target gene expression in atherosclerotic lesions, we administered anti-HB-EGF/NA/b-siRNA against hrGFP (100 or 500 μg/mouse), b-siRNA against only hrGFP (the same amount of 500 μg of anti-HB-EGF/NA/ b-siRNA) or saline to the Hbegf hz/hz; Apoe-/-mice that were fed with a high-fat diet for 30 weeks. As shown in Figure 4B , within the atherosclerotic lesions of the ascending aorta, the expression levels of hrGFP were significantly decreased after administrating a high dose of anti-HB-EGF/NA/b-siRNA against hrGFP. However, a similar decrease was not observed after administrating a low dose of anti-HB-EGF/NA/b-siRNA, only siRNA, or saline.
Discussion
For this study, we developed anti-HB-EGF/NA using crosslinking agents such as sulfo-SMCC and 2-iminothiolane. Both immunostaining and FACS analysis showed that anti-HB-EGF/NA could bind to and undergo internalization within cells that expressed HB-EGF. Note that anti-HB-EGF/NA/b-siRNA knocked down the targeted gene within cells that expressed HB-EGF. The anti-HB-EGF/NA-labeled ATTO700 was accumulated from the ascending to the arch regions of the atherosclerotic aorta. It then knocked down the target gene in atherosclerotic lesions of the ascending aorta. To summarize, siRNA delivery using an anti-HB-EGF Ab could be a promising therapeutic approach for treating ACD. Binding affinity of anti-HB-EGF/NA: In this study, we developed anti-HB-EGF/NA, which demonstrated binding affinity for HB-EGF that was only slightly lesser than that of anti-HB-EGF Ab (Table) . However, anti-HB-EGF/NA retained high-affinity antigen that were bound to similar Ab drugs such as trastuzumab 23) and tocilizumab, both of which are currently used in clinical environments. 24) In vitro targeting and knockdown: Similar to the results of a previous study, 14) the results observed in Figure 2A and 2B revealed that anti-HB-EGF/NA-labeled ATTO488 could bind to and undergo internalization within cells that expressed HB-EGF. Moreover, FACS analysis revealed that~80% of the Ab-conjugated fluorescence that was bound to HB-EGF on the cell surface was internalized within cells that expressed HB-EGF in 24 hours. Compared with a previous study that revealed that Abmediated internalization and degradation of trastuzumab is slow, 25) binding capability of anti-HB-EGF to HB-EGF was high and internalization of the HB-EGF complex was rapid and efficient too.
Importantly, anti-HB-EGF-conjugated siRNA could efficiently knockdown the target molecules within cells that expressed HB-EGF (Figure 3) . These results suggest that anti-HB-EGF/NA/b-siRNA could be internalized within cells via HB-EGF-mediated endocytosis and that certain siRNAs could be released from the endosomes into the cytoplasm. However, mechanisms for the endosomal escape, which is widely considered a key technology for a successful siRNA delivery using non-viral vectors, remains unclear. 26) Therefore, future studies need to focus on an explanation for the underlying mechanism and extent to which siRNA escapes from endosomes. In vivo targeting and knockdown: Note that anti-HB-EGF/NA-labeled ATTO700 gets accumulated from the ascending aorta to the arch region ( Figure 4A) . Previously, Tsuchida, ET AL studies have demonstrated that, in Apoe-/-mice, atherosclerotic plaques that contain a large necrotic core, high macrophage content, and thin fibrous cap eventually develop in such regions. 27) Moreover, macrophages within atherosclerotic plaques express high amounts of HB-EGF. 11, 12) Thus, anti-HB-EGF/NA possibly gets accumulated from the ascending aorta to the arch region.
We generated atherosclerotic mice that expressed human HB-EGF after crossing human HB-EGF knock-in mice with Apoe-/-mice because human anti-HB-EGF does not cross-react with mouse HB-EGF. 22) Note that HrGFP gets transcribed as a bicistronic mRNA with human HB-EGF. 22) Thus, using anti-HB-EGF/NA/b-siRNA against hrGFP, we evaluated gene knockdown after measuring the mRNA levels of hrGFP, which gets expressed along with HB-EGF. For our study, we successfully demonstrated that, in atherosclerotic lesions, anti-HB-EGF/ NA/b-siRNA against hrGFP could knockdown hrGFP gene expression in a dose-dependent manner ( Figure 4B ). Moreover, note that nanoparticles get accumulated in tissues with enhanced vascular permeability such as atherosclerotic lesions. 28, 29) Because average sizes of anti-HB-EGF/NA was~30 nm ( Table) , the accumulation of anti-HB-EGF/NA in atherosclerotic lesions could reflect a combination of active targeting of cells with high HB-EGF expression and enhanced vascular permeability within atherosclerotic lesions. Although data suggest that anti-HB-EGF/NA delivers siRNA within cells that expressed HB-EGF in atherosclerotic lesions and that HB-EGF is expressed on macrophages and SMCs, further studies are required to identify the target cells and molecules for applying anti-HB-EGF-conjugated siRNA to treat atherosclerosis. Gene delivery to atherosclerotic lesions: As a potential treatment for atherosclerosis, many studies have proposed gene therapy using viral vectors. 30, 31) For example, Liu et al. demonstrated that chemoattractant protein-1 gene silencing using adenovirus-mediated shRNA prevented vulnerable plaque disruption in Apoe-/-mice. 32) However, viral vectors are generally associated with safety concerns such as carcinogenesis and immunogenicity; 7) therefore, an efficient and safe gene delivery system is required. To our knowledge, this is the first study to demonstrate the knockdown of target genes in atherosclerotic lesions using Ab-conjugated siRNA. In human clinical trials, ocular adverse events have been reported along with the administration of antibody-drug conjugates. Therefore, this technology could also have similar adverse events; however, most of them are mild in severity and reversible. 33) Thus, this technology could be applied for clinical situations with fewer safety concerns.
7)
Conclusions
In the atherosclerotic lesions of mice, anti-HB-EGF/ NA/b-siRNA knocked down targeted gene expression. Thus, for treating atherosclerotic cardiovascular diseases, siRNA delivery using an anti-HB-EGF/NA could be a promising therapeutic approach.
